Integra LifeSciences Holdings Corporation

NasdaqGS:IART Rapport sur les actions

Capitalisation boursière : US$1.7b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Integra LifeSciences Holdings Gestion

Gestion contrôle des critères 4/4

Le PDG Integra LifeSciences Holdings' est Jan De Witte, nommé en Dec2021, a un mandat de 2.67 ans. La rémunération annuelle totale est $ 6.39M, composée du salaire de 13.7% et des bonus 86.3%, y compris les actions et options de la société. détient directement 0.024% des actions de la société, d'une valeur de $ 395.59K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.3 ans et 11.3 ans.

Informations clés

Jan De Witte

Directeur général

US$6.4m

Rémunération totale

Pourcentage du salaire du PDG13.7%
Durée du mandat du directeur général2.7yrs
Propriété du PDG0.02%
Durée moyenne d'occupation des postes de direction3.3yrs
Durée moyenne du mandat des membres du conseil d'administration11.3yrs

Mises à jour récentes de la gestion

Recent updates

At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?

Jul 01
At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?

Integra LifeSciences Still Underperforming As Manufacturing Issues Linger

Jun 21

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price

May 28
Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

Feb 27
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Feb 11
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jan 14
Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Dec 31
Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Dec 03
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Nov 06
Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Oct 24
Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Sep 22
Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Aug 15
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Jul 03
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jun 19
Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

May 05
Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Apr 07
These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

Mar 26
Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Mar 14
At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?

Feb 27
Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?

Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Feb 02
Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Jan 05
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return

Dec 21
Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return

When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Dec 08
When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 42% Discount?

Oct 19
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 42% Discount?

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Oct 05
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Integra LifeSciences: Wide Dislocation In Fundamentals Vs. Market Value

Sep 13

Is It Time To Consider Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Sep 06
Is It Time To Consider Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Analyse de la rémunération des PDG

Comment la rémunération de Jan De Witte a-t-elle évolué par rapport aux bénéfices de Integra LifeSciences Holdings?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

US$24m

Mar 31 2024n/an/a

US$40m

Dec 31 2023US$6mUS$875k

US$68m

Sep 30 2023n/an/a

US$101m

Jun 30 2023n/an/a

US$131m

Mar 31 2023n/an/a

US$172m

Dec 31 2022US$9mUS$850k

US$181m

Sep 30 2022n/an/a

US$173m

Jun 30 2022n/an/a

US$166m

Mar 31 2022n/an/a

US$157m

Dec 31 2021US$899kUS$59k

US$169m

Rémunération vs marché: La rémunération totale de Jan ($USD 6.39M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 5.62M ).

Rémunération et revenus: La rémunération de Jan a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Jan De Witte (60 yo)

2.7yrs

Titularisation

US$6,388,756

Compensation

Mr. Jan De Witte has been President, Chief Executive Officer & Director of Integra LifeSciences Holdings Corporation since December 1, 2021. He had been the Chief Executive Officer at Barco NV since Septem...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Stuart Essig
Executive Chairman26.7yrsUS$422.52k2.26%
$ 37.8m
Jan De Witte
President2.7yrsUS$6.39m0.024%
$ 395.4k
Lea Knight
Executive VP & CFO1.2yrsUS$1.67m0.054%
$ 903.7k
Jeffrey Mosebrook
Senior VP of Finance & Principal Accounting Officer6.8yrsUS$1.25m0.048%
$ 803.3k
Eric Schwartz
Executive VP5.8yrsUS$1.62m0.082%
$ 1.4m
Robert Davis
Executive VP & President of Tissue Technologies11.7yrsUS$1.42m0.084%
$ 1.4m
Michael McBreen
Executive VP & President of Codman Specialty Surgical4.3yrsUS$2.83m0.075%
$ 1.2m
Stephen Leonard
Corporate VP of Global Operations & Supply Chain4yrspas de donnéespas de données
Laurene Isip
Vice President of Global Corporate Communications & Public Relationsno datapas de donnéespas de données
Ruth Fleming
Vice President of Global Marketingno datapas de donnéespas de données
Chantal Veillon-Berteloot
Executive VP & Chief Human Resources Officer1.6yrspas de données0.033%
$ 555.7k
Mark Jesser
Corporate VP & Chief Digital Officer2.6yrspas de donnéespas de données

3.3yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Gestion expérimentée: L'équipe de direction de IART est considérée comme expérimentée (ancienneté moyenne 3.3 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Stuart Essig
Executive Chairman26.7yrsUS$422.52k2.26%
$ 37.8m
Jan De Witte
President2.7yrsUS$6.39m0.024%
$ 395.4k
Raymond Murphy
Independent Director15.3yrsUS$297.54k0.11%
$ 1.8m
Christian Schade
Independent Director18.6yrsUS$293.28k0.082%
$ 1.4m
Barbara Hill
Independent Presiding Director11.3yrsUS$342.54k0.18%
$ 2.9m
Keith N. Bradley
Independent Director32.6yrsUS$306.31k0.090%
$ 1.5m
Jeffrey Graves
Independent Directorless than a yearUS$90.68k0.016%
$ 269.2k
Shaundra Clay
Independent Director3.3yrsUS$260.04k0.028%
$ 472.5k
Renee Lo
Independent Director2.1yrsUS$297.54k0.021%
$ 348.1k

11.3yrs

Durée moyenne de l'emploi

63yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration IART sont chevronnés et expérimentés (durée moyenne d'administration 11.3 ans).